Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocon Staying Firm On Insulins Path, Including Glargine

Executive Summary

Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.


Related Content

Biosimilars Begin To 'Pay Off' For Biocon
Key Wins In US By Indian Firms - Keep An Eye On These In 2019
Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars
Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Biocon To Buttress India Market Glargine Supply From Malaysia Site
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts